Accuray (ARAY) Plans to Sell 7 Million Shares of Common Stock
Accuray Inc (ARAY) has announced its intention to offer 7 million shares of its common stock for sale, allowing existing shareholders to divest their holdings. The company, which specializes in advanced radiation therapy systems like the CyberKnife, faces financial challenges including a negative EPS, high leverage, and declining margins, with an Altman Z-Score indicating potential bankruptcy risk. Investors are closely watching the market's response to this offering and the stock's future performance.
Accuray posts updated investor presentation, to present to analysts and investors
Accuray has published an updated investor presentation on its investor relations website, as disclosed in a Form 8-K filing on February 17, 2026. Company representatives are scheduled to present these contents to analysts and investors on or after the same date. The presentation, which includes forward-looking statements, provides summary information about the company.
ACCURAY INC SEC 10-Q Report
Accuray Inc. has released its Q2 FY2026 10-Q report, detailing significant financial and operational challenges. The report shows declines in revenue and profitability, impacted by increased costs, lower product sales, and macroeconomic factors like geopolitical tensions affecting the China region. The company expects continued challenges through fiscal year 2026.
Accuray Delays Quarterly Filing After Disclosure Review
Accuray (ARAY) has announced a delay in filing its Form 10-Q for the quarter ended December 31, 2025, due to errors found in its remaining performance obligations disclosure from previous filings. The company expects to submit the report within a five-day extension and states that these errors are not anticipated to affect its Balance Sheets, Statements of Operations, or Cash Flows. Accuray also notes that this is a one-off issue and does not foresee a significant change in its operational results compared to the prior year.
Accuray (NASDAQ:ARAY) Cut to "Sell" at Wall Street Zen
Wall Street Zen downgraded Accuray (NASDAQ:ARAY) from "hold" to "sell" on Saturday, February 7, 2026, contributing to a MarketBeat consensus rating of "Hold" with an average price target of $2.00. The company reported quarterly EPS of ($0.11), meeting estimates, and revenue of $102.24 million, but continues to show negative net margins and strained profitability. Despite institutional investment, shares opened at $0.62, currently trading with a market cap of approximately $70.27 million.
Accuray Disclosed Failure to Satisfy a Continued Listing Rule or Standard
Accuray (ARAY) received a notice from Nasdaq on February 2, 2026, indicating non-compliance with the minimum $1.00 bid price rule, as its stock traded below this threshold for 30 consecutive business days. The company has 180 days, until August 3, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days. An additional 180-day period may be granted if Accuray transfers to the Nasdaq Capital Market.
The Market Doesn't Like What It Sees From Accuray Incorporated's (NASDAQ:ARAY) Revenues Yet As Shares Tumble 33%
Accuray Incorporated's share price has fallen 33% in the last month, contributing to a 78% decline over the past year. The company's low price-to-sales (P/S) ratio of 0.2x, significantly below the industry average, is attributed to recent revenue declines and a projected future growth of only 3.8% compared to the industry's 53%. Investors appear wary of the company's limited growth prospects, reflecting in its suppressed stock valuation.
Accuray Incorporated (NASDAQ:ARAY) Q2 2026 Earnings Call Transcript
Accuray Incorporated reported its Q2 2026 earnings, missing expectations with an EPS of $-0.11 against an expectation of $-0.02. The company announced a comprehensive strategic transformation plan targeting a $25 million improvement in annualized operating profitability, including a 15% workforce reduction. Due to ongoing tariffs and geopolitical instability, particularly in China, the company reduced its fiscal 2026 revenue guidance to $440 million - $450 million and adjusted EBITDA guidance to $22 million - $25 million.
Accuray cuts 15% of staff in $25M overhaul while swinging to loss
Accuray (NASDAQ: ARAY) reported a 12% revenue decline to $102.2 million and a net loss of $13.8 million for Q2 fiscal 2026. In response, the company is implementing a transformation plan, including a 15% workforce reduction, aiming for a $25 million annualized operating profit improvement. Accuray also updated its FY2026 guidance, projecting $440-$450 million in revenue and $22-$25 million in adjusted EBITDA.
Accuray Incorporated (NASDAQ:ARAY) Plunges Over 13% on Weak Guidance Despite Narrow Earnings Beat
Accuray Incorporated (NASDAQ:ARAY) experienced a significant over 13% drop in after-hours trading despite a narrow earnings beat for its fiscal Q2 2026. The market reacted negatively primarily due to weak guidance for future quarters, indicating that investors are more concerned with the company's forward-looking prospects and operational challenges than its past performance. This sharp decline underscores investor skepticism about Accuray's ability to meet future targets for growth and profitability.
Earnings call transcript: Accuray’s Q2 2026 results show revenue dip, stock steady
Accuray Incorporated reported a revenue dip in Q2 2026, reaching $102.2 million against a forecast of $109.11 million, though its EPS of -$0.11 matched expectations. The company's stock remained stable in after-hours trading, reflecting market confidence despite a 12% year-over-year decline in revenue, primarily due to product revenue decreases and geopolitical tensions in China. Accuray has lowered its full-year 2026 revenue guidance to $440-$450 million and is undergoing operational restructuring, including a 15% workforce reduction, to improve profitability and focus on sustainable growth.
Accuray: Fiscal Second Quarter Earnings Overview
Accuray Inc. reported a net loss of $13.8 million, or 11 cents per share, for its fiscal second quarter, a decline compared to a profit in the same period last year. The radiation oncology solutions company generated $102.2 million in revenue. Share value significantly decreased from $2.33 a year prior to 76 cents by the close of trading on Wednesday.
Accuray: Fiscal Second Quarter Earnings Overview
Accuray Inc. reported a net loss of $13.8 million for its fiscal second quarter, equating to 11 cents per share, a decline from a profit in the prior year. The radiation oncology solutions company generated $102.2 million in revenue during this period. Accuray's stock price also saw a significant drop, trading at 76 cents per share compared to $2.33 a year ago.
Accuray earnings matched, revenue fell short of estimates
Accuray (NASDAQ: ARAY) reported second-quarter earnings per share (EPS) of $-0.110, which matched analyst estimates, but its revenue of $102.2 million fell short of the consensus estimate of $109.11 million. The company's guidance for fiscal year 2026 revenue is $440 million to $450 million, below the analyst consensus of $466.7 million. Accuray's stock has seen a significant decline over the last 3 and 12 months, and its financial health is rated as "fair performance."
Accuray Posts Weaker Q2 Results Amid Ongoing Transformation
Accuray (ARAY) reported significantly weaker fiscal Q2 2026 results, with revenue declining 12% year-on-year to $102.2 million and the company swinging to a $13.8 million net loss. In response, Accuray has initiated a major transformation, including staff reductions of about 15% and cost-cutting measures, aiming for $25 million in annualized operating profit improvements. Despite a reaffirmation of strategic goals and updated full-year guidance, the financial performance and market conditions present considerable challenges for the medical technology company.
Accuray: Fiscal Q2 Earnings Snapshot
Accuray Inc. (ARAY) reported a fiscal second-quarter loss of $13.8 million, or 11 cents per share, which contrasts with a profit in the same period last year. The radiation oncology company posted revenue of $102.2 million for the quarter. Its shares were trading at 66 cents, down from $2.35 a year ago.
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for the second quarter of fiscal year 2026, which ended on December 31, 2025, during a conference call on February 4, 2026, at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the call via dial-in numbers or a live webcast on the company's investor relations website, with replays available afterward. Accuray focuses on advancing radiation therapy for cancer treatment and is headquartered in Madison, Wisconsin.
Accuray to Report Second Quarter Fiscal 2026 Financial Results on February 4, 2026
Accuray Incorporated will report its financial results for the second quarter of fiscal year 2026, which ended December 31, 2025, on February 4, 2026. A conference call hosted by company management will take place at 1:30 p.m. PT/4:30 p.m. ET on that date to discuss the results. A live webcast and replay of the call will be available on the company's investor relations website for those unable to attend.
Following a 59% decline over last year, recent gains may please Accuray Incorporated (NASDAQ:ARAY) institutional owners
Institutional investors hold a significant 59% stake in Accuray Incorporated (NASDAQ:ARAY), meaning their trading decisions heavily influence the stock. After experiencing a 59% loss over the past year, these institutional owners are likely pleased with the recent 11% increase in share price. BlackRock, Inc., The Vanguard Group, Inc., and Aevum Pension Fund are among the top shareholders, while company insiders also own a small but notable portion of the stock.
Following a 59% decline over last year, recent gains may please Accuray Incorporated (NASDAQ:ARAY) institutional owners
Accuray Incorporated has seen a 59% decline over the last year, but a recent 11% increase in share price may be welcome news to its institutional owners, who collectively hold 59% of the company. Key institutional investors include BlackRock, Inc., The Vanguard Group, Inc., and Aevum Pension Fund, while company insiders own US$4.8 million worth of stock, and the general public holds a 36% stake. The article suggests that while institutional ownership provides credibility, investors should also consider analyst sentiments and other financial factors.
Following a 59% decline over last year, recent gains may please Accuray Incorporated (NASDAQ:ARAY) institutional owners
Institutional investors, holding 59% of Accuray Incorporated (NASDAQ:ARAY), may be encouraged by a recent 11% share price increase after a year-long 59% decline. BlackRock, Inc. is the largest shareholder with 7.7%, and insiders collectively own US$4.8 million worth of stock. The general public maintains a 36% stake in the company.
Accuray (NASDAQ:ARAY) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen has upgraded Accuray (NASDAQ:ARAY) from a "sell" to a "hold" rating, aligning with the stock's current consensus "Hold" rating and an average price target of $4.00. Despite missing quarterly EPS estimates with a loss of ($0.18) per share, the medical equipment provider slightly exceeded revenue expectations. Accuray, trading around $0.85 with a $96 million market cap and negative profitability metrics, has significant institutional ownership at approximately 64%.
Accuray director Byron C. Scott to retire from board at year-end
Accuray (NASDAQ:ARAY) director Byron C. Scott is retiring from the board, effective December 31, 2025, a decision not related to company disagreements. This follows Accuray's Q1 FY2026 results, which showed a larger-than-expected loss but a revenue beat, alongside a strategic transformation plan to improve profitability and a 15% workforce reduction. BTIG has lowered its price target for Accuray to $4.00, maintaining a Buy rating amidst these developments.
Accuray Incorporated Announces Retirement of Byron C. Scott as Class III Director and Including All Committees, Effective December 31, 2025
Accuray Incorporated announced that Byron C. Scott will retire from its Board of Directors, including all committees, effective December 31, 2025. This decision was not due to any disagreements with the company, its Board, operations, policies, or practices. Mr. Scott served as a Class II director of Accuray.
Accuray Incorporated's (NASDAQ:ARAY) 25% Dip In Price Shows Sentiment Is Matching Revenues
Accuray Incorporated (NASDAQ:ARAY) has experienced a significant 25% drop in its share price over the last month, culminating in a 59% decline over the past year. This poor performance is attributed to sluggish revenue growth compared to competitors in the Medical Equipment industry. The company's low price-to-sales (P/S) ratio of 0.2x reflects investor pessimism, especially given that future revenue growth is projected to be 4.6%, far below the industry forecast of 48%.
Accuray (NASDAQ:ARAY) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen downgraded Accuray (NASDAQ:ARAY) from a "hold" to a "sell" rating, coinciding with a consensus "Hold" rating from other analysts and a $4.00 target price. The company's shares are trading near a 12-month low, and it recently missed quarterly EPS estimates while reporting negative return on equity and net margin, along with a high debt-to-equity ratio. Institutional investors have adjusted their positions in Accuray, with some increasing and others decreasing their stakes.
Accuray (Nasdaq:ARAY) - Stock Analysis
This Simply Wall St analysis of Accuray (Nasdaq:ARAY) highlights the company's financial overview, current stock performance, and future growth prospects. Accuray, which develops and sells radiosurgery and radiation therapy systems, is currently trading significantly below its estimated fair value but faces risks due to unprofitability and a meaningful debt burden. The report provides detailed financial data, recent news, and compares ARAY's performance to its industry and the broader market.
Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital
Accuray (NASDAQ:ARAY) shows concerning trends in its Return on Capital Employed (ROCE), which has declined significantly from 7.5% five years ago to 0.6% currently, underperforming the Medical Equipment industry average. Despite utilizing the same amount of capital, the company's returns are falling, indicating a mature business without recent growth and potential difficulties in capital allocation. These factors contribute to the stock's 80% decline over the past five years, suggesting investors may want to look elsewhere unless these underlying trends improve.
Accuray (NASDAQ:ARAY) May Have Issues Allocating Its Capital
Accuray (NASDAQ:ARAY) appears to be struggling with capital allocation, as evidenced by a declining return on capital employed (ROCE). Their ROCE has fallen significantly over the past five years to a low 0.6%, underperforming the Medical Equipment industry average. This trend suggests the company is in a mature phase with limited growth, which could explain the substantial 80% drop in stock value over the same period.
Wall Street Zen Upgrades Accuray (NASDAQ:ARAY) to Hold
Wall Street Zen upgraded Accuray (NASDAQ: ARAY) from a "sell" to a "hold" rating, leading to an average analyst rating of "Hold" with a consensus target price of $4.00, despite mixed broker views. The company recently missed quarterly EPS expectations but slightly beat revenue forecasts, showing ongoing financial challenges such as a negative net margin and return on equity and trading near its 52-week low. Institutional investors have made various adjustments to their holdings in Accuray.
Accuray to reduce headcount by 15%, outsource non-core activities
Accuray has announced a plan to reduce its global workforce by 15% to optimize efficiency and reduce operating expenses. The restructuring is expected to result in annual cost savings of $20 million to $25 million, with most benefits realized in fiscal year 2026. Non-core activities will be outsourced to further streamline operations.
Accuray cortará 15% da força de trabalho em plano de reestruturação
Accuray Incorporated (NASDAQ:ARAY) anunciou um plano de transformação estratégica visando reduzir sua força de trabalho global em 15% para melhorar a lucratividade operacional em cerca de US$ 25 milhões anualmente. A empresa, especializada em soluções de radioterapia, planeja simplificar sua estrutura comercial, centralizar funções essenciais e otimizar sua força de trabalho e instalações. Esta reestruturação visa focar em vendas e serviços, estabelecendo um ritmo operacional mais eficiente e uma estrutura de custos com margens mais altas.
Radiation Therapy-Focused Accuray Details Workforce Reduction, Outsourcing In Major Transformation Push
Accuray Incorporated (NASDAQ: ARAY) has initiated a major strategic transformation to improve profitability, which includes a workforce reduction of approximately 15%, outsourcing non-core activities, and streamlining operations. These changes are expected to generate $25 million in annualized run-rate operating profitability improvement, with $12 million anticipated in fiscal 2026. Despite near-term restructuring charges, Accuray reaffirmed its full-year fiscal 2026 forecast and reported Q1 2026 sales that beat consensus estimates.
Accuray (NASDAQ: ARAY) details 15% workforce cuts, loan changes, warrants
Accuray Incorporated is implementing a significant restructuring, including a 15% global workforce reduction and amendments to its loan agreement to gain financial flexibility. The company expects approximately $11 million in restructuring charges but anticipates an improvement of $25 million in annualized operating profitability from the first phase of its transformation plan. Additionally, Accuray issued several series of warrants to lenders in exchange for covenant relief and other concessions.
Accuray to cut 15% of workforce in restructuring plan By Investing.com
Accuray Incorporated announced a strategic transformation plan to cut its global workforce by approximately 15%, aiming to boost operating profitability by $25 million annually. This restructuring will streamline commercial operations, centralize core functions, and optimize its workforce and facilities. Despite a recent larger-than-anticipated loss per share, the company has maintained its financial forecasts for fiscal year 2026.
Madison-based medical equipment maker Accuray to lay off 15% of global workforce
Madison-based medical equipment maker Accuray Inc. is set to lay off 15% of its global workforce as part of a major organizational and operational transformation. This move aims to realign the company, enhance execution, and right-size its cost structure, with an expected saving of $12 million in fiscal 2026 and an improvement in operational profitability by $25 million annually once fully implemented. The company anticipates incurring restructuring charges of approximately $11 million.
Accuray Workforce Reduction, Outsourcing In Transformation Push - Accuray (NASDAQ:ARAY)
Accuray (NASDAQ: ARAY) announced a strategic transformation initiative including a 15% global workforce reduction and outsourcing to improve profitability by an annualized $25 million. This move aims to streamline operations, centralize functions, and reallocate resources, with most initiatives expected to be implemented by the end of fiscal 2026. Despite incurring $11 million in restructuring charges, the company reaffirmed its fiscal 2026 sales guidance after missing Q1 2026 earnings expectations.
Accuray announces financing amendments and workforce reduction
Accuray has announced amendments to its financing arrangements including its credit facility and term loan. The company also implemented a workforce reduction affecting approximately 7% of its global non-manufacturing employees to optimize operations and improve financial performance. These actions are projected to result in annual operating expense savings of $12 million to $14 million, with cost reductions reflected sequentially in the third and fourth quarters of fiscal year 2025.
Accuray Incorporated Announces Amendments to Financing Agreement
Accuray Incorporated has announced two amendments to its financing agreement. The first amendment, dated December 12, 2025, modifies the calculation of liquidity to include restricted cash and extends the deadline for complying with certain passive company requirements. The second amendment, dated December 15, 2025, removes the leverage condition for drawing on the delayed draw term loan facility, reduces DDTL commitments to $18.25 million, and delays the start of financial covenant testing until Q1 FY2027.
Accuray stock rises after announcing $25 million cost-cutting plan
Accuray Incorporated (NASDAQ:ARAY) announced a comprehensive transformation plan aimed at improving profitability by approximately $25 million annually, leading to a 5.7% rise in its stock. This plan involves organizational realignment, cost structure optimization, outsourcing, and a 15% reduction in the global workforce. The company expects to realize $12 million of the profit improvements in fiscal 2026 and will incur restructuring charges of approximately $11 million.
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
Accuray Incorporated announced the first phase of a comprehensive strategic, operational, and organizational transformation plan aimed at improving annualized operating profitability by approximately $25 million. This phase involves organizational realignment, rightsizing the cost structure, outsourcing, and sales enablement, affecting about 15% of the company's employees. The company expects to realize approximately $12 million of the projected profit improvement in fiscal year 2026 and incur about $11 million in restructuring charges.
Accuray to cut 15% of workforce in restructuring plan
Accuray Inc. announced a strategic transformation plan to reduce its global workforce by approximately 15%, aiming to improve operating profitability by about $25 million annually. The radiation therapy equipment maker expects to save $12 million in fiscal year 2026 and incur about $11 million in restructuring charges. Despite an recent Q1 FY2026 revenue beat, the company posted a larger-than-anticipated loss per share, leading to a reduced price target from BTIG.
Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximately $25 million and set the stage for renewed growth
Accuray Incorporated (NASDAQ: ARAY) has announced the first phase of a comprehensive transformation plan aimed at improving operating profitability by approximately $25 million annually and preparing for renewed growth. This phase includes organizational realignment, cost structure rightsizing, outsourcing, and sales enablement, which will impact approximately 15% of the company's employees. Accuray expects to realize about $12 million of the projected profit improvement in fiscal year 2026.
Accuray Incorporated (NASDAQ:ARAY) is largely controlled by institutional shareholders who own 59% of the company
Institutional shareholders collectively own 59% of Accuray Incorporated (NASDAQ:ARAY), giving them significant influence over the company's share price. BlackRock, Inc. is the largest shareholder with 7.7%, and the top 24 shareholders together own 50% of the company. Insiders also hold shares, demonstrating alignment with other shareholders, while the general public owns 36%.
Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding
Accuray Incorporated's shares have dropped significantly, falling 28% in the last month and 51% over the past year. The company's low price-to-sales (P/S) ratio of 0.3x, compared to an industry average of 3.3x, reflects concerns about its revenue growth, which has been sluggish and is forecast to remain materially lower than the broader Medical Equipment industry. This lack of perceived growth potential is leading to low investor sentiment and a suppressed P/S ratio for ARAY.
Little Excitement Around Accuray Incorporated's (NASDAQ:ARAY) Revenues As Shares Take 28% Pounding
Accuray Incorporated's shares have fallen 28% over the last month, contributing to a 51% loss over the past year. The company's low price-to-sales (P/S) ratio of 0.3x compared to an industry average of 3.3x reflects sluggish revenue growth and a forecast for future growth that is materially lower than the broader medical equipment industry. This indicates a lack of investor confidence in Accuray's future prospects.
Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden
Accuray Incorporated (NASDAQ: ARAY) carries a meaningful debt burden, with net debt of US$76.8m as of September 2025. The company's weak interest cover and high net debt to EBITDA ratio indicate a heavy debt load and potential risks. However, Accuray's ability to convert EBIT into free cash flow and its position in the defensive Medical Equipment industry offer some optimistic signs.
Accuray Stockholders Approve 2026 Equity Incentive Plan
Accuray stockholders approved the 2026 Equity Incentive Plan during their Annual Meeting on November 13, 2025. They also elected Class I directors, conducted an advisory vote on executive compensation, and ratified Grant Thornton LLP as the independent registered public accounting firm. TipRanks' AI Analyst, Spark, rates ARAY as Neutral due to challenging financial performance, bearish technical indicators, high leverage, and negative profitability.
Accuray Q1 FY26 presentation slides: Revenue declines 7% but guidance maintained
Accuray (NASDAQ:ARAY) reported a 7% year-over-year revenue decline in Q1 FY26, primarily due to a 23% drop in product revenue, but maintained its full-year guidance for FY26. The company's stock rose 5.43% after hours, reflecting investor optimism for its strategic initiatives, including the launch of the new Stellar system. Challenges remain regarding profitability, the impact of its China JV, and competitive pressures, which the company plans to address through a transformation plan.
Accuray Inc expected to post a loss of 6 cents a share - Earnings Preview
Accuray Inc (ARAY) is projected to report a loss of 6 cents per share and a 10.0% decrease in quarterly revenue to $91.35 million when it releases its results for the period ending September 30, 2025. Analysts currently have a "strong buy" rating on the stock, with a median 12-month price target of $4.75, representing a 70.3% upside from its last closing price.
